phosphatidylcholines has been researched along with Ewing Sarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, T; Jia, SF; Kleinerman, ES; Worth, LL | 1 |
| Jeha, SS; Kleinerman, ES; Worth, LL | 1 |
1 review(s) available for phosphatidylcholines and Ewing Sarcoma
| Article | Year |
|---|---|
Biologic response modifiers in pediatric cancer.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytokines; Drug Design; Hematopoietic Cell Growth Factors; Humans; Immunologic Factors; Immunotherapy; Infant; Interleukins; Isotretinoin; Liposomes; Neoplasms; Neuroblastoma; Osteosarcoma; Phosphatidylcholines; Phosphatidylethanolamines; Phosphatidylglycerols; Salvage Therapy; Sarcoma, Ewing | 2001 |
1 other study(ies) available for phosphatidylcholines and Ewing Sarcoma
| Article | Year |
|---|---|
ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Breast Neoplasms; Carcinoma; Cells, Cultured; Cytokines; Cytotoxicity, Immunologic; Gene Expression Regulation; Humans; Interleukins; Liposomes; Macrophage-Activating Factors; Melanoma; Monocytes; Osteosarcoma; Phosphatidylcholines; Phosphatidylglycerols; Sarcoma, Ewing; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1999 |